1-11 of 11
Amy F. McLemore
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes

David Sallman, Amy F McLemore, Rami S. Komrokji, Hany Elmariah, Andrew T. Kuykendall, Nelli Bejanyan, Onyee Chan, Rawan Faramand, Joseph A. Pidala, Sean J. Yoder, Lia Perez, Taiga Nishihori, Eric Padron, Hugo Francisco Fernandez, Jeffrey E Lancet, Asmita Mishra
Journal: Blood
Blood (2024) 144 (Supplement 1): 1046.
https://doi.org/10.1182/blood-2024-203903
Published: 2024
Journal Articles

Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)

David Sallman, Amy F McLemore, Onyee Chan, Andrew T. Kuykendall, Eric Padron, Zhuoer Xie, Alison R. Walker, David H Spencer, Rami S. Komrokji, Jeffrey E Lancet, Meagan Jacoby
Journal: Blood
Blood (2024) 144 (Supplement 1): 4332.
https://doi.org/10.1182/blood-2024-205211
Published: 2024
Journal Articles

XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies

Traci L. Kruer, Ariel Quintana, Meghan Ferrall-Fairbanks, Ling Zhang, Hannah Newman, Amy F McLemore, Qin Yang, Nana Bencrentsil, Rami S. Komrokji, Sana Chaudhry, Tulasigeri M Totiger, Maria Ken E. Figueroa, Justin Taylor, David A. Sallman, Eric Padron
Journal: Blood
Blood (2022) 140 (Supplement 1): 99–100.
https://doi.org/10.1182/blood-2022-169765
Published: 2022
Journal Articles

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

David A. Sallman, Rami S. Komrokji, Amy E. DeZern, Marie Sebert, Guillermo Garcia-Manero, Ramy Rahmé, David P. Steensma, Jacqueline Lehmann che, Gail J. Roboz, Isabelle Madelaine, Mikkael A. Sekeres, Pierre Peterlin, Kendra Sweet, Odile Beyne Rauzy, Andrew T. Kuykendall, Christian Recher, Amy F McLemore, Aspasia Stamatoullas, Ling Zhang, Lise Willems, Qianxing Mo, Emmanuel Raffoux, Lisa Nardelli, Celine Berthon, Najla Al Ali, Bruno Quesnel, Eric Padron, Greg Korbel, Eyal C. Attar, Hagop Kantarjian, Alan F. List, Lionel Ades, Jeffrey E. Lancet, Pierre Fenaux, Thomas Cluzeau
Journal: Blood
Blood (2021) 138 (Supplement 1): 246.
https://doi.org/10.1182/blood-2021-153286
Published: 2021
Journal Articles

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

David A. Sallman, Amy F. McLemore, Amy L. Aldrich, Rami S. Komrokji, Kathy L. McGraw, Abhishek Dhawan, Susan Geyer, Hsin-An Hou, Erika A. Eksioglu, Amy Sullivan, Sarah Warren, Kyle J. MacBeth, Manja Meggendorfer, Torsten Haferlach, Steffen Boettcher, Benjamin L. Ebert, Najla H. Al Ali, Jeffrey E. Lancet, John L. Cleveland, Eric Padron, Alan F. List
Journal: Blood
Blood (2020) 136 (24): 2812–2823.
https://doi.org/10.1182/blood.2020006158
Published: 2020
Includes: Supplemental data
Journal Articles

Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

David A Sallman, MD, Amy E. DeZern, MD, Guillermo Garcia-Manero, MD, David P. Steensma, MD, Gail J. Roboz, MD, Mikkael A. Sekeres, MD MS, Thomas Cluzeau, MD PhD, Kendra L. Sweet, MD, Amy F McLemore, M.S., Kathy McGraw, PhD, John Puskas, PhD, Ling Zhang, MD, Jiqiang Yao, PhD, Qianxing Mo, PhD, Lisa Nardelli, Najla Al Ali, M.Sc, Eric Padron, MD, Greg Korbel, PhD MBA, Eyal C. Attar, MD, Hagop M. Kantarjian, MD, Jeffrey E. Lancet, MD, Pierre Fenaux, MD PhD, Alan F. List, MD, Rami S. Komrokji, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 676.
https://doi.org/10.1182/blood-2019-131055
Published: 2019
Journal Articles

Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes

Grace A Ward, BS, Kathy McGraw, PhD, Amy F McLemore, M.S., Nghi B Lam, M.S., Hsin-An Hou, Benjamin S. Meyer, Alan F. List, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 774.
https://doi.org/10.1182/blood-2019-122358
Published: 2019
Journal Articles

Dysregulation of Splicing Patterns in MDS Induced By the S100A9/Fto Axis

Erika Adriana Eksioglu, MS PhD, Ling Cen, PhD, Xianghong Chen, PhD, Pingyan Cheng, MD, Kenneth Wright, PhD, Thu Le Trinh, PhD, Danielle Gilvary, BS, Wendy Kandell, BS, Jinhong Liu, MD, Yin-Kai Chen, MD, Amy F McLemore, M.S., Alexandra Calescibetta, John Cleveland, PhD, Alan F. List, MD, Sheng Wei, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4215.
https://doi.org/10.1182/blood-2019-128434
Published: 2019
Journal Articles

Genomic-DNA Exposed By Somatic Gene Mutations Engages the cGAS/STING Axis to License the NLRP3 Inflammasome in Myelodysplastic Syndromes

Amy F McLemore, M.S., Kathy L McGraw, PhD, Hsin-An Hou, MD PhD, Grace A Ward, BS, Alexis H Onimus, BS, Nicole D. Vincelette, PhD, Matthew A. Rodrigues, PhD, Neelkamal Chaudhary, PhD, Ling Zhang, MD, Benjamin S. Meyer, Erika A Eksioglu, PhD MS, Sheng Wei, MD, Alan F. List, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3075.
https://doi.org/10.1182/blood-2018-99-116929
Published: 2018
Journal Articles

Oxidized Mitochondrial DNA Is a Catalyst and Biomarker of Pyroptotic Cell Death in Myelodysplastic Syndromes

Grace A Ward, BS, Kathy L McGraw, PhD, Amy F McLemore, M.S., Farnoosh Abbas-Aghababazadeh, PhD, Hsin-An Hou, MD PhD, Thu Le Trinh, PhD, Nicole D. Vincelette, PhD, Benjamin S. Meyer, Alexis H Onimus, BS, Alexandra Calescibetta, Erika A Eksioglu, PhD MS, Sheng Wei, MD, Alan F. List, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3076.
https://doi.org/10.1182/blood-2018-99-118493
Published: 2018
Journal Articles

Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

David A Sallman, MD, Amy E. DeZern, MD, David P. Steensma, MD, Kendra L. Sweet, MD, Thomas Cluzeau, MD PhD, Mikkael A. Sekeres, MD MS, Guillermo Garcia-Manero, MD, Gail J. Roboz, MD, Amy F McLemore, M.S., Kathy L McGraw, PhD, John Puskas, PhD, Ling Zhang, MD, Chirag K Bhagat, PharmD, Jiqiang Yao, PhD, Najla Al Ali, M.Sc, Eric Padron, MD, Roger Tell, MD PhD, Jeffrey E. Lancet, MD, Pierre Fenaux, MD PhD, Alan F. List, MD, Rami S. Komrokji, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3091.
https://doi.org/10.1182/blood-2018-99-119990
Published: 2018